About

AGC Biologics specializes in the development and manufacturing of therapeutic proteins, plasmid DNA, viral vectors, and genetically engineered cells for the biopharmaceutical industry. The company provides a full range of services from initial development to large-scale production, catering to clients from small biotech firms to large pharmaceutical companies. Their facilities, located in the U.S., Europe, and Asia, adhere to strict quality regulations to ensure the safety and efficacy of the products. AGC Biologics stands out by offering fast-track project capabilities, particularly for orphan drugs and rare diseases, which require quicker development timelines. The company's goal is to support biopharmaceutical companies in bringing new treatments to market efficiently and effectively, while continuously enhancing their technical capabilities and innovation.

Simplify's Take

What believers are saying

• Increased demand for plasmid DNA boosts AGC's gene therapy and vaccine services.
• Partnership with BioConnection enhances biodrug development capabilities, attracting more clients.
• Expansion in Yokohama aligns with growing mRNA and cell therapy demand.

What critics are saying

• Restructuring and layoffs in Colorado indicate potential financial instability.
• Leadership changes may disrupt ongoing projects and affect client trust.
• Significant investment in Japan could strain financial resources and divert focus.

What makes AGC Biologics unique

• AGC Biologics specializes in therapeutic proteins, plasmid DNA, and viral vectors.
• The company offers fast-track project capabilities for orphan drugs and rare diseases.
• AGC Biologics operates globally with facilities in the U.S., Europe, and Asia.

Help us improve and share your feedback! Did you find this helpful?

YesNo